OncoMatch/Clinical Trials/NCT06341660
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Is NCT06341660 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies cadonilimab for non-small cell lung cancer.
Treatment: cadonilimab — To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: STK11 mutation
STK11 mutations were detected by NGS
Required: EGFR wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Required: ALK wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Required: ROS1 wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Required: RET wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Required: MET wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Required: HER2 (ERBB2) wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Required: BRAF wild-type
no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping)
Allowed: PD-L1 (CD274) expression
patients can provide eligible tumor tissue for PD-L1 expression level measurement
Disease stage
Required: Stage POSTOPERATIVE RECURRENT (AJCC 8th edition)
advanced or postoperative recurrent non-small cell lung cancer (AJCC 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor therapy
Exception: Patients who had received one prior chemotherapy regimen were allowed, regardless of whether chemotherapy was administered before, after, or concurrently with targeted therapy.
The patient had not received systemic antitumor therapy. Patients who had received one prior chemotherapy regimen were allowed, regardless of whether chemotherapy was administered before, after, or concurrently with targeted therapy.
Lab requirements
Blood counts
had good major organ function, defined as meeting the following criteria, and had not received blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of study medication
Kidney function
had good major organ function, defined as meeting the following criteria, and had not received blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of study medication
Liver function
had good major organ function, defined as meeting the following criteria, and had not received blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of study medication
had good major organ function, defined as meeting the following criteria, and had not received blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of study medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify